We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current MRSN market cap is 260.63M. The company's latest EPS is USD -1.4030 and P/E is -1.50.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 7.8M | 10.65M | 7.7M | 10.7M | 9.25M |
| Operating Income | -57.8M | -56.5M | -43.94M | -21.43M | -21M |
| Net Income | -56.16M | -54.31M | -41.66M | -19.54M | -19.31M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 42.12M | 828k | 43k | 26.58M | 36.86M |
| Operating Income | -30.2M | -88.11M | -168.86M | -203.77M | -179.67M |
| Net Income | -28.21M | -88.05M | -170.06M | -204.21M | -171.67M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 296.2M | 311M | 262.9M | 226.06M | 198.37M |
| Total Liabilities | 231.9M | 221.2M | 210.71M | 189.16M | 170.39M |
| Total Equity | 64.29M | 89.8M | 52.2M | 36.9M | 27.99M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 107.54M | 273.4M | 206.11M | 334.34M | 226.06M |
| Total Liabilities | 29.22M | 45.31M | 84.37M | 242.28M | 189.16M |
| Total Equity | 78.32M | 228.09M | 121.74M | 92.06M | 36.9M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -29.01M | -90.84M | -136.92M | -168.88M | -32.66M |
| Investing | 1.4M | -4.04M | 99.74M | 119.88M | -72.55M |
| Financing | 21.55M | 94.73M | 94.58M | 94.68M | 5.83M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -67.74M | -74.7M | -139.99M | -49.36M | -168.88M |
| Investing | -27.29M | 37.03M | -648k | -152.72M | 119.88M |
| Financing | 97.7M | 230.41M | 63.65M | 153.02M | 94.68M |
| Market Cap | 260.63M |
| Price to Earnings Ratio | -1.50 |
| Price to Sales Ratio | 7.01 |
| Price to Cash Ratio | 1.48 |
| Price to Book Ratio | 7 |
| Dividend Yield | - |
| Shares Outstanding | 122.36M |
| Average Volume (1 week) | 1.54M |
| Average Volume (1 Month) | 1.48M |
| 52 Week Change | -38.08% |
| 52 Week High | 6.2801 |
| 52 Week Low | 0.8014 |
| Spread (Intraday) | 3.03 (60.6%) |
| Company Name | Mersana Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.mersana.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
